MiMedx Group, Inc. (MDXG) Market Cap & Valuation Ratios
MiMedx Group, Inc. (MDXG) has a market cap of $569.9M, a trailing P/E of 97.8 and a price-to-sales ratio of 1.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MDXGMiMedx Group, Inc.Follow MDXG — free
—
Price chart with a free account
- Market cap
- 569.9M
- P/E TTM
- 97.8
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| MDXG | 0.6 | 97.8 | 1.3 | 5.7 | 7.8% | -2% | 2% | 4% |
| WVE | 0.6 | — | 4.0 | — | — | -30% | -333% | -255% |
| CADL | 0.6 | — | — | — | -9.3% | — | — | — |
| CRMD | 0.6 | 3.8 | 1.1 | 2.0 | — | +281% | 47% | 57% |
| SGMT | 0.6 | — | — | — | -7.0% | — | — | -59% |
| CLYM | 0.6 | — | — | — | -9.3% | — | — | -36% |
| IMMX | 0.6 | — | — | — | -6.7% | — | — | — |
| ZVRA | 0.6 | 10.7 | 2.7 | 4.3 | 5.6% | +119% | 61% | 68% |
| DBVT | 0.6 | — | 80.2 | — | — | +29% | — | — |
| OLMA | 0.6 | — | — | — | — | — | — | -65% |
| ACRS | 0.6 | — | 56.0 | — | -11.3% | -51% | — | -82% |
| Median of these 10 | 7.2 | 4.0 | 3.1 | -8.2% | +29% | 47% | -59% |
P/E 97.8 vs. a peer median of 7.2; EV/Sales 1.3 vs. 4.0. MDXG's own P/E sits at the 94th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesWVE and CADL and SGMT and CLYM and IMMX and DBVT and OLMA and ACRS have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
MiMedx Group, Inc. — questions
- What is MiMedx Group, Inc.'s market cap?
- $569.9M.
- What is MiMedx Group, Inc.'s P/E ratio?
- 97.8 on trailing twelve-month earnings to 2026-06-30.
- What is MiMedx Group, Inc.'s price-to-sales ratio?
- 1.6.
Every figure on this page comes from MiMedx Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.